Product Information
TIZANIDINE HCL 2 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.0901 per EA under NDC 00591278886. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 29, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591278886
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TIZANIDINE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021447FDA Approved
8/29/2002
TE Code
AB
On Market Since
2/6/2012
Pharmacological Classes
Price Statistics
The NADAC for TIZANIDINE HCL 2 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 95.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0901 per EA |
|---|---|
| All-time high | $2.0934 (Aug 13, 2014) |
| All-time low | $0.0693 (May 17, 2023) |
| 52-week high | $0.0932 |
| 52-week low | $0.0804 |
| Median price | $0.3281 |
| Average price | $0.6600 |
| Largest weekly change | +60.8% (Jul 22, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tizanidine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central alpha-2 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIZANIDINE HCL 2 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TIZANIDINE HCL 2 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.0901 per EA (NDC 00591278886), effective Sep 30, 2026.
How has the price of TIZANIDINE HCL 2 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TIZANIDINE HCL 2 MG CAPSULE has declined 95.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TIZANIDINE HCL 2 MG CAPSULE?
Since Nov 28, 2013, the NADAC for TIZANIDINE HCL 2 MG CAPSULE has ranged from a low of $0.0693 (May 17, 2023) to a high of $2.0934 (Aug 13, 2014), with a median of $0.3281 per EA.
Are there cheaper alternatives to TIZANIDINE HCL 2 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TIZANIDINE HCL 2 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures TIZANIDINE HCL 2 MG CAPSULE?
TIZANIDINE HCL 2 MG CAPSULE (NDC 00591278886) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.